Anti-viral guanidino-substituted compounds
CA 2176760 A1 · Owner: Allelix Biopharmaceuticals Inc. · Inventors: Rakhit, Sumanas; Slassi, Abdelmalik
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel guanidino-substituted compounds are described having general formula (I) or a salt, hydrate or solvate thereof, wherein X is selected from C O, N and , S; R1 is -(W)a-(R4)b-Z, wherein a and b are independently 0 or 1; W is NH O , or S; R4 is C1-8alkylene in which one or two of the carbon atoms thereof is optionally replaced with nitrogen or oxygen; and Z is H OH or -NH-C(NH)-NH2; , R2 and R3 are, independently C1-8alkylene in which one of the carbon atoms thereof is optionally replaced with nitrogen or oxygen. These compounds have been found to inhibit effectively herpesvirus replication. Particularly preferred compounds in accordance with formula (I) for this purpose are …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 16, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 16, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 16, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.